164 related articles for article (PubMed ID: 32171575)
41. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
42. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
[TBL] [Abstract][Full Text] [Related]
44. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.
Knight GM; Griffiths UK; Sumner T; Laurence YV; Gheorghe A; Vassall A; Glaziou P; White RG
Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15520-5. PubMed ID: 25288770
[TBL] [Abstract][Full Text] [Related]
45. Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia.
Gargano LM; Hajjeh R; Cookson ST
Prehosp Disaster Med; 2015 Aug; 30(4):402-11. PubMed ID: 26061190
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
[TBL] [Abstract][Full Text] [Related]
47. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
48. The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.
Knerer G; Currie CSM; Brailsford SC
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008805. PubMed ID: 33095791
[TBL] [Abstract][Full Text] [Related]
49. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
[TBL] [Abstract][Full Text] [Related]
50. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
Hoshi SL; Seposo X; Okubo I; Kondo M
Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
[TBL] [Abstract][Full Text] [Related]
52. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
[TBL] [Abstract][Full Text] [Related]
55. Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
Niyibitegeka F; Riewpaiboon A; Youngkong S; Thavorncharoensap M
Vaccine; 2021 Feb; 39(8):1272-1282. PubMed ID: 33487467
[TBL] [Abstract][Full Text] [Related]
56. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
57. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
